NWHFC logo


The following resources include articles, documents, and webpages with information on current heart failure treatments and other information to aid your practice.

Drugs That May Cause or Exacerbate Heart Failure

This scientific statement from the American Heart Association is designed to serve as a comprehensive and accessible source of drugs that may cause or exacerbate heart failure to assist healthcare providers in improving the quality of care for these patients.

Exploring the Future of Heart Failure (HF) Management.

This activity, provided by Purdue University and PeerView Institute for Medical Education, Inc., has been designed to meet the continuing educational needs of cardiologists and other clinicians involved in the treatment and management of patients with chronic heart failure. In this activity, experts G. Michael Felker, MD, MHS, FACC, FAHA (Duke University School of Medicine, Durham, NC) and Scott David Solomon, MD (Harvard Medical School, Brigham and Women’s Hospital, Boston, MA) discuss treatment strategies for chronic heart failure and related readmission rates. Upon completion of this activity, participants should be better able to: describe the pathophysiologic mechanisms associated with HFpEF and HFrEF, and approved therapeutic agents that interact with these pathways; recognize approved and emerging treatment strategies for chronic heart failure based on their clinical efficacy and safety; and employ evidence-based approaches to reduce chronic heart failure–related readmission rates and mortality and improve patient quality of life. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Release and Expiration Dates: June 30, 2016 – June 29, 2017.
Time to Complete: 30 minutes.

2016 European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and chronic heart failure.

The aim of the ESC Guidelines is to help health professionals to make decisions in their everyday life based on the best available evidence. These guidelines were developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the ESC. Members of this Task Force were selected by the ESC to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for management (including diagnosis, treatment, prevention and rehabilitation) of a given condition according to ESC Committee for Practice Guidelines policy. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the risk-benefit ratio. Estimates of expected health outcomes for larger populations were included, where data exist.

2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America developed in collaboration with the International Society for Heart and Lung Transplantation. To keep pace with evolving evidence, the American College of Cardiology (ACC)/American Heart Association (AHA) Task Force on Clinical Practice Guidelines (“Task Force”) has issued this focused update to reassess guideline recommendations on the basis of recently published study data. This update has been subject to rigorous, multilevel review and approval, similar to the full guidelines. For specific focused update criteria and additional methodological details, please see the ACC/AHA guideline methodology manual.